Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label study to evaluate the long-term safety, tolerability and efficacy of OMS906 in patients with paroxysmal nocturnal hemoglobinuria (PNH)

Next Previous
Search
Trial Profile

An open-label study to evaluate the long-term safety, tolerability and efficacy of OMS906 in patients with paroxysmal nocturnal hemoglobinuria (PNH)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zaltenibart (Primary)
  • Indications Paroxysmal nocturnal haemoglobinuria
  • Focus Adverse reactions
  • Sponsors Omeros Corporation

    • Most Recent Events

    • 10 Dec 2024 According to an Omeros Corporation media release, the company presented data of this trial at the 66th Annual Meeting of the American Society of Hematology (ASH) yesterday in San Diego
    • 24 Oct 2024 According to an Omeros Corporation media release, the company has recently held productive meetings with regulatory authorities - an end-of-phase 2 meeting with FDA and a scientific advice meeting in Europe., clearing its path to initiate phase 3 studies for zaltenibart in PNH later in Q4 2024.
    • 01 Apr 2024 Status changed from recruiting to active, no longer recruiting, according to an Omeros Corporation media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top